Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation
- 1 December 2015
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 170 (6) , 1151-1160
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Portola Pharmaceuticals
This publication has 28 references indexed in Scilit:
- Inflammation in Atrial FibrillationJACC, 2012
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 2012
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersStatistics in Medicine, 2010
- Update on the Association of Inflammation and Atrial FibrillationJournal of Cardiovascular Electrophysiology, 2010
- Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF)Clinical Science, 2009
- Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul StudyAmerican Heart Journal, 2008
- High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial FibrillationStroke, 2007
- Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillationAmerican Heart Journal, 2004
- Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failureAmerican Heart Journal, 2004
- Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available.The American Journal of Cardiology, 1998